The cost of drug development: a systematic review.

By S. Morgan, Paul Grootendorst, J. Lexchin, Colleen Cunningham, Devon L. Greyson. 2011

498 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery (2013, background): “approved new chemical entity (NCE) continue to soar[1-3],”
The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation (2014, unknown): “8 billion for the development of a novel therapeutic agent [1].”
Structure-aware generation of drug-like molecules (2021, background): “1 Introduction Increasing attrition rates in drug design [1, 2, 3] will require higher automation [4] for screening the vast space of ∼ 10(60) drug-like chemicals [5] and proposing novel substances.”
3D bioactive composite scaffolds for bone tissue engineering (2017, background): “The cost of performing preclinical and human clinical trials is substantial, and can extend to hundreds of millions of dollars [446,447].”
Machine Learning Methods in Drug Discovery (2020, background): “While quite diverse and speciﬁc to candidates, the cost of drug discovery and development has consistently and dramatically increased [5].”